In Vivo., Toxicity and Pharmacokinetic Features of B43(Anti-CD19)-Genistein Immunoconjugate

Leukemia and Lymphoma

Volumn 30, Issue 42067, 1998, Pages 389-394

  ek, Onur ^a,b   Yanishevskic, Yuri ^c   Zeren, Tamer ^a   Waurzyniak, Barbara ^b   Gunther, Roland ^a   Chelstrom, Lisa ^b   Chandan Langlie, Mridula ^d   Schneider, Elizabeth ^b   Myers, Dorothea E ^d   Evans, William ^c   Uckun, Fatih M ^a  

^a Wayne Hughes Institute   (Italy)

^b University of Minnesota   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d Alexander and Parker Corporation   (United States)

Author keywords

anti CD19 genistein immunoconjugate; B43; in vivo toxicity; pharmacokinetics

Indexed keywords

ANTIBODY CONJUGATE; ANTILEUKEMIC AGENT; CD19 ANTIGEN; GENISTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; FEMALE; GENISTEIN; HUMANS; IMMUNOCONJUGATES; LEUKEMIA, B-CELL; MICE; MICE, INBRED BALB C; MICE, SCID;

EID: 7344234242     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199809057550     Document Type: Article

References (6)

1. Uckun F.M., Evans W.E., Forsyth C.J., Waddick K.G., T-Ahlgren L., Chelstrom L.M., Burkhardt A., Bolen J., Myers D.E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 1995; 267: 886 – 891
2. Myers D.E., Jun X., Waddick K.G., Forysth C., Chelstrom L.M., Gunther R.L., Turner N.E., Bolen J., Uckun F.M. Membrane-associated CD19-LYN complex is an endogenous p53-independent and bcl-2-independent regulator of apoptosis in human B-lineage lymphoma cells. Proc Nat'l Acad Sci USA. 1995; 92: 9575 – 9579
3. Myers D.E., Sicheneder A., Clementson D., Dvorak N., Venkatachalam T., Rostovsev A., Chandan-Langlie M., Uckun F.M. Large scale manufacturing of B43(anti-CD19)-Genistein for clinical trials in leukemia and lymphoma. Leukemia and Lymphoma 1997, in press
4. Gunther R., Chelstrom L.M., Wendorf H.R., Schneider E.A., Covalciuc K., Johnson B., Clementson D., Irvin J.D., Myers D.E., Uckun F.M. Toxicity profile of the investigational biotherapeutic agent, B43 (anti-CD 19)-pokeweed antiviral protein immunotoxin. Leukemia and Lymphoma 1996; 22: 61 – 70
5. Waurzyniak B., Lisowski E., Wendorf H., Chelstrom L., Myers D.E., Irvin J., Ek O., Zeren T., Yanishevski Y., Langlic M., Evans W., Messinger Y., Gunther R., Uckun F.M. Pharmacokinetic features, toxicity and in vivo., anti-leukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clinical Cancer Research 1997; 3: 881 – 890
6. Gerlowski L.E., Jain R.K. Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci. 1983; 72: 1103 – 1126